Analyst consensus rating
Pfizer Analyst Rating: Buy
Direct answer
Pfizer's consensus rating is Buy.
26 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $30.22.
Forecast evidence checked November 14, 2026.
Get free Pfizer email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $28.89
- Average price target
- $30.22
- High price target
- $37.00
- Low price target
- $25.00
- Low target gap
- -13.5%
- Target upside
- +4.6%
- High target gap
- +28.1%
- Target range width
- 41.5%
- Consensus rating
- Buy
- Analysts
- 26
- Evidence date
- November 14, 2026
- Valid through
- November 21, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Pfizer?
Pfizer has a verified Buy consensus. The same dataset has an average price target of $30.22.
How far are Pfizer's low and high targets from the recorded price?
The low target implies -13.5%, while the high target implies +28.1%.
How many analysts are included in Pfizer's consensus?
The verified consensus includes 26 analysts.
How is Pfizer's target upside or downside calculated?
The average target of $30.22 is divided by the recorded price of $28.89, then one is subtracted to produce +4.6%. This does not guarantee a future return.
When was Pfizer's analyst forecast verified?
The data was verified on 2026-11-14. The dataset is valid through 2026-11-21.